<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21658">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01855412</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-0001-P</org_study_id>
    <nct_id>NCT01855412</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes</brief_title>
  <acronym>LIBERTY</acronym>
  <official_title>LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Systems Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Systems Inc</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate acute and long term clinical and economic outcomes
      of endovascular procedures to treat Peripheral Arterial Disease (PAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational, multi-center, clinical study examining the
      effectiveness of endovascular treatment of peripheral artery disease among patients
      undergoing revascularization of  lesions within the target area within 10 cm above the
      medial epicondyle to the digital arteries.  This includes disease in the distal superficial
      femoral artery (SFA), popliteal (POP), tibial peroneal trunk (TPT), anterior tibial (AT),
      posterior tibial (PT), and peroneal tibial (PR) arteries.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Procedural success of Endovascular PAD Treatment(s)</measure>
    <time_frame>After the last subject's 5-year follow-up visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Final post-procedural result of &lt; 30% residual stenosis for all treated lesions during index procedure and without angiographic complications as determined by the Angiographic Core Laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion Success of Endovascular PAD Treatment(s)</measure>
    <time_frame>After the last subject's 5-year follow-up visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Final post-procedural result of &lt; 30% residual stenosis for a given lesion treated during index procedure without angiographic complications as determined by the Angiographic Core Laboratory.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Major Adverse Events (MAEs)</measure>
    <time_frame>After the last subject's 5-year follow-up visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate of the following MAEs as reported by the Investigators will be assessed during the subject's participation in the study:
Death
Unplanned major (above the ankle) amputation of the index limb
Clinically-driven TLR (Target Lesion Revascularization) and/or TVR (Target Vessel Revascularization) of the index limb</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Peripheral Arterial Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>Claudication (Rutherford 2-3)</arm_group_label>
    <description>Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3.  Patients may be treated with any FDA-cleared endovascular PAD treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLI Rutherford 4-5</arm_group_label>
    <description>Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5.  Patients may be treated with any FDA-cleared endovascular PAD treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLI Rutherford 6</arm_group_label>
    <description>Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6.  Patients may be treated with any FDA-cleared endovascular PAD treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PAD endovascular treatments</intervention_name>
    <description>All FDA-cleared endovascular PAD treatments</description>
    <arm_group_label>Claudication (Rutherford 2-3)</arm_group_label>
    <arm_group_label>CLI Rutherford 4-5</arm_group_label>
    <arm_group_label>CLI Rutherford 6</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been determined by their physician to require endovascular device
        treatment for their PAD.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject's age â‰¥ 18 years.

          -  Subject presents with a Rutherford classification of  2 to 6.

          -  Subject presents with clinical evidence of PAD requiring endovascular intervention
             that includes a target lesion located within 10 cm above the medial epicondyle to the
             digital arteries.  For the subjects with a wound on the index limb, the target lesion
             should be considered the lesion in the vessel which provides blood flow to the wound.

        Exclusion Criteria:

          -  Subject is unwilling or unable to sign the IRB (Institutional Review Board) approved
             informed consent form (ICF).

          -  Subject is unable to understand or comply with the study protocol requirements.

          -  Subject is currently participating in an investigational drug or other device study
             that can clinically interfere with the endpoints of this study.

          -  Subject is pregnant or planning to become pregnant within the study period.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Ansel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riverside Methodist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rex Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jihad Mustapha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metro Health Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Fugal, MS</last_name>
      <phone>203-785-4855</phone>
      <email>patricia.fugal@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Indes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bart Muhs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Aruny, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cassius Chaar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hamid Mojibian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bauer Sumpio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Purvis, RN</last_name>
      <phone>407-303-5600</phone>
      <phone_ext>1102019</phone_ext>
      <email>tracey.purvis@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Mark Ranson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohit Bhatheja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nipun Arora, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Wladis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Varnagy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delos Clift, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Winter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shady Grove Adventist Hospital</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Carney, RN, BSN</last_name>
      <phone>240-826-6177</phone>
      <email>kcarney@adventisthealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Silva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shan Haider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health Hospital</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa McGoff, RN</last_name>
      <phone>616-252-8116</phone>
      <email>theresa.mcgoff@metrogr.org</email>
    </contact>
    <investigator>
      <last_name>Jihad Mustapha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Karenko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larry Diaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fadi Saab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gotham Cardiovascular</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Liu, NP</last_name>
      <phone>646-660-9991</phone>
      <email>mliu@nycva.net</email>
    </contact>
    <investigator>
      <last_name>Cezar Staniloae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lori Vales, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seol Hwang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rex Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Krejci, RN, MSN</last_name>
      <phone>919-784-4279</phone>
      <email>patrick.krejci@rexhealth.com</email>
    </contact>
    <investigator>
      <last_name>George Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Zidar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohit Pasi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deepak Pasi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 15, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>LIBERTY</keyword>
  <keyword>Observational</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
